Skip to main content
. Author manuscript; available in PMC: 2022 Nov 18.
Published in final edited form as: Eur Radiol. 2022 Apr 29;32(11):7448–7462. doi: 10.1007/s00330-022-08815-2

Table 4.

Diagnostic performance of HDMI biomarkers for predicting the status of ER, PR, HER2, Ki-67 and molecular subtypes in malignant masses.

Immunohistochemical
biomarkers
BAmean ap
value
FD ap value NV ap
value
NB ap
value
ER 0.141 0.259 0.950 0.908
 Negative (25) 68.3±45.2 1.2±0.3 13.6±12.3 6.2±5.8
 Positive (159) 80.6±44.1 1.1±0.2 14.0±14.6 6.6±7.9
PR 0.711 0.020 0.019 0.026
 Negative (38) 80.6±40.7 1.2±0.3 18.6±14.9 8.6±7.8
 Positive (146) 78.5±45.4 1.1±0.2 12.7±14.0 6.0±7.6
HER2 0.393 0.036 0.004 0.016
 Negative (159) 77.1±40.1 1.1±0.2 12.6±13.6 5.9±7.3
 Positive (25) 90.6±30.1 1.2±0.2 22.4±16.3 10.4±9.2
Ki-67 0.209 0.036 0.001 0.004
 <0.14 (113) 75.7±46.0 1.2±0.2 12.4±14.2 5.8±7.4
 ≥0.14 (71) 84.1±41.4 1.1±0.3 16.4±14.2 7.7±8.0
Subtypes 0.047 0.776 0.018 0.050
 Luminal A (77) 74.3±47.5 1.1±0.2 11.2±14.1 5.3±7.5
 Luminal B (HER2+) (61) 84.5±44.2 1.1±0.2 14.3±13.3 6.7±7.4
 Luminal B (HER2−) (21) 92.4±24.7 1.2±0.3 23.7±16.6 11.1±9.6
 HER2+ (4) 81.1±54.8 1.2±0.2 15.8±14.5 7.3±6.4
 TN (21) 65.8±44.3 1.2±0.3 13.2±12.2 5.9±5.9

Number in parentheses are lesion numbers.

a

A p value smaller than 0.05 indicates significance.